Assembly Biosciences Announces Participation in the Microbiome Movement Drug Development Summit

Date : 06/25/2019 @ 8:05PM
Source : GlobeNewswire Inc.
Stock : Assembly Biosciences Inc (ASMB)
Quote : 16.82  0.02 (0.12%) @ 2:45PM

Assembly Biosciences Announces Participation in the Microbiome Movement Drug Development Summit

Assembly Biosciences (NASDAQ:ASMB)
Historical Stock Chart

1 Year : From Jan 2019 to Jan 2020

Click Here for more Assembly Biosciences Charts.

Assembly Biosciences, Inc. (NASDAQ: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome, today announced participation in the Microbiome Movement Drug Development Summit, to be held June 26-28, 2019 in Boston.

Assembly will participate in the following presentation and panels at the Summit:

Presentation: Discovery and Development of Rationally-Selected Consortia of Live Microbial Biotherapeutics Based on Disease Relevant MechanismsPresenter: Jackie Papkoff, PhD, Senior Vice President, Chief Scientific Officer Microbiome Date/Time: Thursday, June 27, 2019 at 3:10pm ET

Panel: Manufacturing and Scaling Live Biotherapeutic Products (LBP)Panelist: Wayne Herber, PhD, Senior Vice President Biological ManufacturingDate/Time: Thursday, June 27, 2019 at 12pm ET

Panel: New Perspectives on Pharmaceutical & Biotech Partnerships in the MicrobiomePanelist: Micah Mackison, Senior Vice President Corporate Development & StrategyDate/Time: Friday, June 28, 2019 at 12:30pm ET

About Assembly BiosciencesAssembly Biosciences, Inc. is a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome. The HBV program is focused on advancing a new class of potent, oral core inhibitors that have the potential to increase cure rates for chronically infected patients. The microbiome program is developing novel oral live microbial biotherapeutic candidates with Assembly’s fully integrated platform, including a robust process for strain identification and selection, GMP banking and production, and targeted delivery to the lower gastrointestinal tract with the GEMICEL® technology. For more information, visit assemblybio.com.

Contacts Assembly Biosciences, Inc. Investors: Lauren Glaser (415) 521-3828 lglaser@assemblybio.com 

Latest ASMB Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.